Req. No. 1540 Page 1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
STATE OF OKLAHOMA
1st Session of the 59th Legislature (2023)
SENATE BILL 475 By: Paxton
AS INTRODUCED
An Act relating to the Uniform Controlled Dangerous
Substances Act; amending 63 O.S. 2021, Section 2-101,
as amended by Section 4, Chapte r 265, O.S.L. 2022 (63
O.S. Supp. 2022, Section 2 -101), which relates to
definitions; defining certain term; amending 63 O.S.
2021, Section 2-304, which relates to den ial,
revocation, or suspension of regi stration;
authorizing certain action ; modifying certain
registration suspension and revocation guidelines;
authorizing certain penalty assessment; authori zing
certain drug cleanup and registration guidelines;
amending 63 O.S. 2021, Section 2 -305, which relates
to the order to show cause; modifying certain
registration guidelines ; requiring certain
registration guideline; amending 63 O.S. 2021,
Section 2-322, which relates to precursor substances
requiring permit or license; removing certain
statutory reference; amending 63 O.S. 2021, Section
2-325, which relates to denial, revocation, or
suspension of registra tion; modifying certain
requirement; requiring certain registration
guideline; amending 63 O.S. 2021, Section 2 -406,
which relates to penalties; adding certain unlawful
act; and declaring an emergency.
BE IT ENACTED BY THE PEOPLE OF THE STATE OF O KLAHOMA:
SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -101, as
amended by Section 4, Ch apter 265, O.S.L. 2022 (63 O.S. Sup p. 2022,
Section 2-101), is amended to read as foll ows:
Req. No. 1540 Page 2 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Section 2-101. As used in the Uniform Controlled Dangerous
Substances Act:
1. “Administer” means the direct application of a controlled
dangerous substance, whether by injection, inhalation, ingestion or
any other means, to the body of a patient, animal or research
subject by:
a. a practitioner (or, in the presence of the
practitioner, by the authorized agent of the
practitioner), or
b. the patient or research subject at the direction and
in the presence of the practitioner;
2. “Agent” means a peace officer appointed by and who acts on
behalf of the Director of the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control or an author ized person who acts on behalf
of or at the direction of a person who manufactures, distrib utes,
dispenses, prescribes, administers or uses for scientific purposes
controlled dangerous substances but does not include a common or
contract carrier, public wa rehouser or employee thereof, or a person
required to register under the Uniform Controlled Dangerous
Substances Act;
3. “Board” means the Advisory Board to the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
4. “Bureau” means the Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control;
Req. No. 1540 Page 3 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
5. “Coca leaves” includes cocaine and any compound,
manufacture, salt, derivative, mixture or preparation of coca
leaves, except derivatives of coca leaves which do not contain
cocaine or ecgonine;
6. “Commissioner” or “Director” means the Director of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
7. “Control” means to add, remove or change the placement of a
drug, substance or immediate precursor under the Unif orm Controlled
Dangerous Substances Act;
8. “Controlled dangerous substance” means a drug, substance or
immediate precursor in Schedules I through V of the Uniform
Controlled Dangerous Substances Act or any drug, substance or
immediate precursor listed ei ther temporarily or permanently as a
federally controlled substance. Any conflict between state and
federal law with regard to the particular schedule in which a
substance is listed shall be resolved in favor of state law;
9. “Counterfeit substance” means a controlled substance which,
or the container or labeling of which without authorization , bears
the trademark, trade name or other identifying marks, imprint,
number or device or any likeness thereof of a manufacturer,
distributor or dispenser other tha n the person who in fact
manufactured, distributed or dispensed the substance;
10. “Deliver” or “delivery” means the actual, constructive or
attempted transfer from one person to another of a controlled
Req. No. 1540 Page 4 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
dangerous substance or drug paraphernalia, whether o r not there is
an agency relationship;
11. “Dispense” means to deliver a controlled dangerous
substance to an ultimate user or human research subject by or
pursuant to the lawful order of a practitioner, including the
prescribing, administering, packaging , labeling or compounding
necessary to prepare the substance for such distribution.
“Dispenser” is a practitioner who delivers a controlled dangerous
substance to an ultimate user or human research subject;
12. “Distribute” means to deliver other than by administering
or dispensing a controlled dangerous substance;
13. “Distributor” means a commercial entity engaged in the
distribution or reverse distribution of narcotics and dangerous
drugs and who complies with all regulations promulgated by the
federal Drug Enforcement Administration and the Oklahoma State
Bureau of Narcotics and Dangerous Drugs Control;
14. “Drug” means articles:
a. recognized in the official United States Pharmacopeia,
official Homeopathic Pharmacopoeia of the United
States, or official National Formulary, or any
supplement to any of them,
b. intended for use in the diagn osis, cure, mitigation,
treatment or prevention of disease in man or other
animals,
Req. No. 1540 Page 5 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
c. other than food, intended to affect the structure or
any function of the body of man or other animals, and
d. intended for use as a component of any article
specified in this paragraph;
provided, however, the term “drug” does not include devices or their
components, parts or accessories;
15. “Drug-dependent person” means a person who is using a
controlled dangerous substance and who is in a state of psychic or
physical dependence, or both, arising from administration of that
controlled dangerous substance on a continuous basis. Drug
dependence is characterized by behavioral and oth er responses which
include a strong compulsion to take the substance on a continuous
basis in order to experience its psychic effects, or to avoid the
discomfort of its absence;
16. “Home care agency” means any sole proprietorship,
partnership, associatio n, corporation, or other organization which
administers, offers, or provides home care serv ices, for a fee or
pursuant to a contract for such services, to clients in their place
of residence;
17. “Home care services” means skilled or personal care
services provided to clients in their place of residence for a fee;
18. “Hospice” means a centrally administered, nonprofit or for-
profit, medically directed, nurse-coordinated program which provides
a continuum of home and inpatient care for the terminally ill
Req. No. 1540 Page 6 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
patient and the patient’s family. Such term shall also include a
centrally administered, n onprofit or for-profit, medically directed,
nurse-coordinated program if such program is licensed pursuant to
the provisions of the Uniform Controlled Dangerous Subs tances Act.
A hospice program offers palliative and supportive care to meet the
special needs arising out of the physical, emotional and spiritual
stresses which are experienced during the final stages of illness
and during dying and bereavement. This care is available twenty-
four (24) hours a day, seven (7) days a week, and is provided on the
basis of need, regardless of ability to pay. “Class A” Hospice
refers to Medicare-certified hospices. “Class B” refers to all
other providers of hospice services;
19. “Imitation controlled substance” means a substance that is
not a controlled dangerous substance, which by dosage unit
appearance, color, shape, size, markings or by representations made,
would lead a reasonable person to believe that the substance is a
controlled dangerous substance. In the event the appearance of the
dosage unit is not r easonably sufficient to establish that the
substance is an “imitation controlled substance”, the court or
authority concerned should consider, in addition to all oth er
factors, the following factors as related to “representations made”
in determining wheth er the substance is an “imitation controlled
substance”:
Req. No. 1540 Page 7 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. statements made by an owner or by any other person in
control of the substance concerning the nature of the
substance, or its use or effect,
b. statements made to the recipient that the substance
may be resold for inordinate profit,
c. whether the substance is packaged in a manner normally
used for illicit controlled substances,
d. evasive tactics or actions utilized by the owner or
person in control of the substance to avoid detection
by law enforcement authorities,
e. prior convictions, if any, of an owner, or any other
person in control of the object, under state or
federal law related to controlled substances or fraud,
and
f. the proximity of the substances to controlled
dangerous substances;
20. “Immediate precursor” means a substance which the Director
has found to be and by regulation designates as being the principal
compound commonly used or produced primarily for use, and which is
an immediate chemical intermediary used, or likely to be us ed, in
the manufacture of a controlled dangerous substance, the control of
which is necessary to prevent, curtail or limit such manufacture;
21. “Laboratory” means a laboratory approved by the Director as
proper to be entrusted with the custody of control led dangerous
Req. No. 1540 Page 8 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
substances and the use of controlled dangerous substances for
scientific and medical purposes and for purposes of instruction;
22. “Manufacture” means the production, preparation,
propagation, compounding or processing of a controlled dangerous
substance, either directly or indirectly by extraction from
substances of natural or synthetic origin, or independently by means
of chemical synthesis or by a combination of extraction and chemical
synthesis. “Manufacturer” includes any person who pac kages,
repackages or labels any container of any controlled dangerous
substance, except practitioners who dispense or compound
prescription orders for delivery to the ultimate consumer;
23. “Marijuana” means all parts of the plant Cannabis sativa
L., whether growing or not; the seeds thereof; the resin extracted
from any part of such plant; and every compound, manufacture, salt,
derivative, mixture or preparation of such plant, its seeds or
resin, but shall not include:
a. the mature stalks of such plant o r fiber produced from
such stalks,
b. oil or cake made from the seeds of such plant,
including cannabidiol derived from the seeds of the
marijuana plant,
c. any other compound, manufacture, salt, derivative,
mixture or preparation of such mature stalks (ex cept
Req. No. 1540 Page 9 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the resin extracted therefrom), including cannabidiol
derived from mature stalks, fiber, oil or cake,
d. the sterilized seed of such plant which is incapable
of germination,
e. for any person participating in a clinical trial to
administer cannabidiol for the treatment of severe
forms of epilepsy pursuant to Section 2-802 of this
title, a drug or substance approved by the federal
Food and Drug Administration for use by those
participants,
f. for any person or the parents, legal guardians or
caretakers of the person who have received a written
certification from a physician licensed in this state
that the person has been diagnosed by a physician as
having Lennox-Gastaut syndrome, Dravet syndrome, also
known as severe myoclonic epilepsy of infancy, or any
other severe form of epilepsy that is not adequately
treated by traditional medical therapies, spasticity
due to multiple sclerosis or due to paraplegia,
intractable nausea and vomiting, appetite stimulation
with chronic wasting diseases, the substance
cannabidiol, a nonpsychoactive cannabinoid, found in
the plant Cannabis sativa L. or any other preparation
thereof, that has a tetrahydrocannabinol concentration
Req. No. 1540 Page 10 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
of not more than three-tenths of one percent (0.3%)
and that is delivered to the patient in the form of a
liquid,
g. any federal Food-and-Drug-Administration-approved drug
or substance, or
h. industrial hemp, from the plant Cannabis sativa L. and
any part of such plant, whether growing or not, with a
delta-9 tetrahydrocannabinol concentration of not more
than three-tenths of one percent (0.3%) on a dry-
weight basis which shall only be grown pursuant to the
Oklahoma Industrial Hemp Program and may be shipped
intrastate and interstate;
24. “Medical purpose” means an intention to utilize a
controlled dangerous substance for physical or mental treatment, for
diagnosis, or for the prevention of a disease condition not in
violation of any state or federal law and not for the purpose of
satisfying physiological or psychological dependence or other abuse;
25. “Mid-level practitioner” means an Advanced Practice
Registered Nurse as defined and within parameters specified in
Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
animal euthanasia technician as defined in Section 698.2 of Title 59
of the Oklahoma Statutes, or an animal control officer registered by
the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
under subsection B of Section 2-301 of this title within the
Req. No. 1540 Page 11 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
parameters of such officer’s duties under Sections 501 through 508
of Title 4 of the Oklahoma Statutes;
26. “Narcotic drug” means any of the following, whether
produced directly or indirectly by extraction from substances of
vegetable origin, or independently b y means of chemical synthesis,
or by a combination of e xtraction and chemical synthesis:
a. opium, coca leaves and opiates,
b. a compound, manufacture, salt, derivative or
preparation of opium, coca leaves or opiates,
c. cocaine, its salts, optical and geo metric isomers, and
salts of isomers,
d. ecgonine, its derivatives, their salts, isomers and
salts of isomers, and
e. a substance, and any compound, manufacture, salt,
derivative or preparation thereof, which is chemically
identical with any of the substan ces referred to in
subparagraphs a through d of this pa ragraph, except
that the words “narcotic drug” as used in Section 2-
101 et seq. of this title shall not include
decocainized coca leaves or extracts of coca leaves,
which extracts do not contain cocain e or ecgonine;
27. “Opiate” or “opioid” means any Schedule II, III, IV or V
substance having an addiction-forming or addiction-sustaining
liability similar to morphine or being capable of conversion into a
Req. No. 1540 Page 12 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
drug having such addiction-forming or addiction -sustaining
liability. The terms do not include, unless specifically designated
as controlled under the Uniform Controlled Dangerous Substances Act,
the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
salts (dextromethorphan). The terms do include the racemic and
levorotatory forms;
28. “Opium poppy” means the plant of the species Papaver
somniferum L., except the seeds thereof;
29. “Peace officer” means a police officer, sheriff, deputy
sheriff, district attorney’s investigator, investigato r from the
Office of the Attorney General, or any other person elected or
appointed by law to enforce any of the criminal laws of this state
or of the United States;
30. “Person” means an individual, corporation, government or
governmental subdivision or agency, business trust, estate, trust,
partnership or association, or any other legal entity;
31. “Poppy straw” means all parts, except the seeds, of the
opium poppy, after mowing;
32. “Practitioner” means:
a. (1) a medical doctor or osteopathic physicia n,
(2) a dentist,
(3) a podiatrist,
(4) an optometrist,
(5) a veterinarian,
Req. No. 1540 Page 13 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(6) a physician assistant or Advanced Practice
Registered Nurse under the supervision of a
licensed medical doctor or osteopathic physician,
(7) a scientific investigator, or
(8) any other person,
licensed, registered or otherwise permitted to
prescribe, distribute, dispense, conduct research with
respect to, use for scientific purposes or administer
a controlled dangerous substance in the course of
professional practice or research in this state, or
b. a pharmacy, hospital, laboratory or other institution
licensed, registered or otherwise permitted to
distribute, dispense, conduct research with respect
to, use for scientific purposes or administer a
controlled dangerous substance in the course of
professional practice or research in this state;
33. “Production” includes the manufacture, planting,
cultivation, growing or harvesting of a controlled dangerous
substance;
34. “State” means the State of Oklahoma or any other state of
the United States;
35. “Ultimate user” means a person who lawfully possesses a
controlled dangerous substance for the person’s own use or for the
use of a member of the person’s household or for administration to
Req. No. 1540 Page 14 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
an animal owned by the person or by a member of the person’s
household;
36. “Drug paraphernalia” means all equipment, products and
materials of any kind which are used, intended for use, or fashioned
specifically for use in planting, propagating, cultivating, growing,
harvesting, manufacturing, comp ounding, converting, producing,
processing, preparing, testing, analyzing, packaging, repackaging,
storing, containing, concealing, injecting, ingesting, inhaling or
otherwise introducing into the human body, a controlled dangerous
substance in violation o f the Uniform Controlled Dangerous
Substances Act including, but not limited to:
a. kits used, intended for use, or fashioned specifically
for use in planting, propagating, cultivating, growing
or harvesting of any species of plant which is a
controlled dangerous substance or from which a
controlled dangerous substance can be derived,
b. kits used, intended for use, or fashioned specifically
for use in manufacturing, compounding, converting,
producing, processing or preparing controlled
dangerous substances ,
c. isomerization devices used, intended for use, or
fashioned specifically for use in increasing the
potency of any species of plant which is a controlled
dangerous substance,
Req. No. 1540 Page 15 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. testing equipment used, intended for use, or fashioned
specifically for use in identifying, or in analyzing
the strength, effectiveness or purity of controlled
dangerous substances,
e. scales and balances used, intended for use, or
fashioned specifically for use in weighing or
measuring controlled dangerous substances,
f. diluents and adulterants, such as quinine
hydrochloride, mannitol, mannite, dextrose and
lactose, used, intended for use, or fashioned
specifically for use in cutting controlled dangerous
substances,
g. separation gins and sifters used, intended for use, or
fashioned specifically for use in removing twigs and
seeds from, or in otherwise cleaning or refining,
marijuana,
h. blenders, bowls, containers, spoons and mixing devices
used, intended for use, or fashioned specifically for
use in compounding controlled dange rous substances,
i. capsules, balloons, envelopes and o ther containers
used, intended for use, or fashioned specifically for
use in packaging small quantities of controlled
dangerous substances,
Req. No. 1540 Page 16 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
j. containers and other objects used, intended for use,
or fashioned specifically for use in parenterally
injecting controlled dangerous substances into the
human body,
k. hypodermic syringes, needles and other objects used,
intended for use, or fashioned specifically for use in
parenterally injecting controlled dan gerous substances
into the human body,
l. objects used, intended for use, or fashioned
specifically for use in ingesting, inhaling or
otherwise introducing marijuana, cocaine, hashish or
hashish oil into the human body, such as:
(1) metal, wooden, acrylic, glass, stone, plastic or
ceramic pipes with or without screens, permanent
screens, hashish heads or punctured metal bowls,
(2) water pipes,
(3) carburetion tubes and devices,
(4) smoking and carburetion masks,
(5) roach clips, meaning objects used to hold burning
material, such as a marijuana cigarette, that has
become too small or too short to be held in the
hand,
(6) miniature cocaine spoons and cocaine vials,
(7) chamber pipes,
Req. No. 1540 Page 17 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(8) carburetor pipes,
(9) electric pipes,
(10) air-driven pipes,
(11) chillums,
(12) bongs, or
(13) ice pipes or chillers,
m. all hidden or novelty pipes, and
n. any pipe that has a tobacco bowl or chamber of less
than one-half (1/2) inch in diameter in which there is
any detectable residue of any controlled dangerous
substance as defined in this section or any other
substances not legal for possession or use;
provided, however, the term “drug paraphernalia” shall not include
separation gins intended for use in preparing tea or spice, clamps
used for constructing electrical equipme nt, water pipes designed for
ornamentation in which no detectable amount of an illegal substance
is found or pipes designed and used solely for smoking tobacco,
traditional pipes of an American Indian tribal religious ceremony,
or antique pipes that are th irty (30) years of age or older;
37. a. “Synthetic controlled substance” means a substance:
(1) the chemical structure of which is substantially
similar to the chemical structure of a controlled
dangerous substance in Schedule I or II,
Req. No. 1540 Page 18 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(2) which has a stimulant, depressant, or
hallucinogenic effect on the cent ral nervous
system that is substantially similar to or
greater than the stimulant, depressant or
hallucinogenic effect on the central nervous
system of a controlled dangerous substance in
Schedule I or II, or
(3) with respect to a particular person, which such
person represents or intends to have a stimulant,
depressant, or hallucinogenic effect on the
central nervous system that is substantially
similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the
central nervous system of a controlled dangerous
substance in Schedule I or II.
b. The designation of gamma butyrolactone or any other
chemical as a precursor, pursuant to Section 2-322 of
this title, does not preclude a findin g pursuant to
subparagraph a of this paragraph that the chemical is
a synthetic controlled substance.
c. “Synthetic controlled substance” does not include:
(1) a controlled dangerous substance,
(2) any substance for which there is an approved new
drug application,
Req. No. 1540 Page 19 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(3) with respect to a particular person any
substance, if an exemption is in effect for
investigational use, for that person under the
provisions of Section 505 of the Federal Food,
Drug and Cosmetic Act, Title 21 of the United
States Code, Section 355, to the extent conduct
with respect to such subst ance is pursuant to
such exemption, or
(4) any substance to the extent not intended for
human consumption before such an exemption takes
effect with respect to that substance.
d. Prima facie evidence that a substance containing
salvia divinorum has been en hanced, concentrated or
chemically or physically altered shall give rise to a
rebuttable presumption that the substance is a
synthetic controlled substance;
38. “Tetrahydrocannabinols” means all substances that have been
chemically synthesized to emulate the tetrahydrocannabinols of
marijuana, specifically including any tetrahydrocannabinols derived
from industrial hemp;
39. “Isomer” means the optical isomer, except as used in
subsections C and F o f Section 2-204 of this title and paragraph 4
of subsection A of Section 2-206 of this title. As used in
subsections C and F of Section 2-204 of this title, “isomer” means
Req. No. 1540 Page 20 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the optical, positional or geometric isomer. As used in paragraph 4
of subsection A of Section 2-206 of this title, the term “isomer”
means the optical or geometric isomer;
40. “Hazardous materials” means materials, whether solid,
liquid or gas, which are toxic to human, animal, aquatic or plant
life, and the disposal of which materia ls is controlled by state or
federal guidelines;
41. “Anhydrous ammonia” means any substance that exhibits
cryogenic evaporative behavior and tests positive for ammonia;
42. “Acute pain” means pain, whether resulting from disease,
accidental or intentional trauma or other cause, that the
practitioner reasonably expects to last only a short period of time.
“Acute pain” does not include chronic pain, pain being treated as
part of cancer care, hospice or other end-of-life care, or pain
being treated as part of palliative care;
43. “Chronic pain” means pain that persists beyond the usual
course of an acute disease or healing of an injury. “Chronic pain”
may or may not be associated with an acute or chronic pathologic
process that causes continuous or intermittent pain over months or
years;
44. “Initial prescription” means a prescription issued to a
patient who:
Req. No. 1540 Page 21 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. has never previously been issued a prescription for
the drug or its pharmaceutical equivalent in the past
year, or
b. requires a prescription for the drug or its
pharmaceutical equivalent due to a surgica l procedure
or new acute event and has previously had a
prescription for the drug or its pharmaceutical
equivalent within the past year.
When determining whether a patient was previously issued a
prescription for a drug or its pharmaceutical equivalent, th e
practitioner shall consult with the patient and review the medical
record and prescription monitoring information of the patient;
45. “Patient-provider agreement” means a written contract or
agreement that is executed between a practitioner and a patien t,
prior to the commencement of treatment for chronic pain using an
opioid drug as a means to:
a. explain the possible risk of development of physical
or psychological dependence in the patient and prevent
the possible development of addiction,
b. document the understanding of both the practitioner
and the patient regarding the patient-provider
agreement of the patient,
c. establish the rights of the patient in association
with treatment and the obligations of the patient in
Req. No. 1540 Page 22 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
relation to the responsible use, discontinuation of
use, and storage of opioid drugs, including any
restrictions on the refill of prescriptions or the
acceptance of opioid prescriptions from practitioners,
d. identify the specific medications and other modes of
treatment, including physical therapy or exercise,
relaxation or psychological counseling, that are
included as a part of the patient-provider agreement,
e. specify the measures the practitioner may employ to
monitor the compliance of the patient including, but
not limited to, rand om specimen screens and pill
counts, and
f. delineate the process for terminating the agreement,
including the consequences if the practitioner has
reason to believe that the patient is not complying
with the terms of the agreement. Compliance with the
“consent items” shall constitute a valid, informed
consent for opioid therapy. The practitioner shall be
held harmless from civil litigation for failure to
treat pain if the event occurs because of nonadherence
by the patient with any of the provisions of the
patient-provider agreement;
46. “Serious illness” means a medical illness or physical
injury or condition that substantially affects quality of life for
Req. No. 1540 Page 23 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
more than a short period of time. “Serious illness” includes, but
is not limited to, Alzheimer’s disease or related dementias, lung
disease, cancer, heart failure, renal failure, liver failure or
chronic, unremitting or intractable pain such as neuropathic pain;
and
47. “Straw person or party ” means a third party who is p ut up
in name only to take part in a transaction. This term includes but
is not limited to a n ominal party to a transaction , one who acts as
an agent for another for the purpose of taking tit le to property and
executing whatever documents and instruments the principal may
direct respecting the property, or a person who purchases property
for another to conceal the identity of the real purchaser or to
accomplish some purpose otherwise not allowed; and
47. 48. “Surgical procedure” means a procedure that is
performed for the purpose of struct urally altering the human body by
incision or destruction of tissues as part of the practice of
medicine. This term includes the diagnostic or therapeutic
treatment of conditions or disease processes by use of instruments
such as lasers, ultrasound, ioniz ing, radiation, scalpels, probes or
needles that cause localized alteration or transportation of live
human tissue by cutting, burning, vaporizing, freezing, suturing,
probing or manipulating by closed reduction for major dislocations
or fractures, or othe rwise altering by any mechanical, thermal,
light-based, electromagnetic or chemical means.
Req. No. 1540 Page 24 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SECTION 2. AMENDATORY 63 O.S. 20 21, Section 2-304, is
amended to read as follows:
Section 2-304. A. A registration, pursuant to Section 2-303 of
this title, to manufacture, distribute, dispense, prescribe,
administer or use for scientific purposes a controlled dan gerous
substance shall be limited, conditioned, den ied, suspended,
annulled, or revoked by the Director upon a finding that the
registrant:
1. Has materially falsified any application filed pursuant to
the Uniform Controlled Dangerous Substances Act or required by t he
Uniform Controlled Dangerous Substanc es Act. It shall be unlawful
to knowingly and willfully:
a. make false statements, include fa lse data or omit
material information on an application for a
registration with the Oklahoma State Bureau of
Narcotics and Dangerous Drugs Control, or
b. provide false data or omit material information in any
records or reports required by rule or law to be
created, maintained or submitted to the Bureau .
Any registrant or applicant for a registration or any official,
agent or employee of any registrant or applicant for a registration
who violates the provisions of this paragraph shall be guilty of a
misdemeanor and additionally subject to administrative action ;
Req. No. 1540 Page 25 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. Has been found guilty of, entered a plea of guilty or
entered a plea of nolo contendere to a misdemean or relating to any
substance defined herein as a controlled dangerous substance or any
felony under the laws of any state or the United States;
3. Has had his or her federal registration retired, suspended
or revoked by a competent federal authority and i s no longer
authorized by federal la w to manufacture, distribute, dispense,
prescribe, administer or use for scientific purposes controlled
dangerous substances;
4. Has failed to maintain effective controls against the
diversion of controlled dangerous su bstances to unauthorized persons
or entities;
5. Has prescribed, dispensed or administered a controlled
dangerous substance from schedules other than those specified in his
or her state or federal registration;
6. Has had a restriction, suspension, revoc ation, limitation,
condition or probation placed on his or her professional license or
certificate or practice as a result of a proceeding pursuant to the
general statutes;
7. Is abusing or, within the past five (5) years, has abused or
excessively used drugs or controlled dangerous sub stances;
8. Has prescribed, sold, administered or ordered any controlled
substance for an immediate family member, himself or herself;
Req. No. 1540 Page 26 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
provided that this shall not apply to a medical emergency when no
other doctor is availa ble to respond to the emergency ;
9. Has possessed, used, prescribed, dispensed or administere d
drugs or controlled dangerous substances for other than legitimate
medical or scientific purposes or for purposes outsid e the normal
course of his or her profes sional practice;
10. Has been under the influence of alcohol or another
intoxicating substanc e which adversely affected the central nervous
system, vision, hearing or other sensory or motor functioning to
such degree the person was impaired during the per formance of his or
her job; or
11. Has violated any federal law relating to any controlled
substances, any provision of the Uniform Controlled Dangerous
Substances Act or any rules of the Oklahoma State Bureau of
Narcotics and Dangerous Drugs Control.
B. In the event the Director suspends or revokes a registration
granted under Section 2-303 of this title, all controlled dangerous
substances owned or possessed by the registrant pursuant to such
registration at the t ime of denial revocation or suspension or the
effective date of the revocation order, as the case may be, may in
the discretion of the Director be impounded and preserved . All
controlled dangerous substances not impounded or preserved by the
Director shall be maintained by the registrant . No disposition,
purchase, distribution , sale, or transfer may be made of substances
Req. No. 1540 Page 27 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
impounded and preserved until the time for taking an appeal has
elapsed or until all appeals have been concluded unless a court,
upon application therefor, orders the sale of p erishable substances
and the deposit of the proceeds of the sale with the court. Upon a
revocation order becoming final, all such co ntrolled dangerous
substances shall be forfeited to the state or otherwise considered
waste and submitted to a licensed was te disposal service for
destruction pursuant to Section 430 of this title.
C. The Drug Enforcement Administration shall promptly be
notified of all orders suspending or revoking registration and all
forfeitures of controlled dangerous substances.
D. In lieu of or in addition to any other remedies available to
the Director, if a finding is made that a registrant has committed
any act in violation of federal law relating to any controlled
substance, any provision of the Uniform Controlled Dangerous
Substances Act or any rules of the Oklahoma State B ureau of
Narcotics and Dangerous Drugs Control, the Director is hereby
authorized to assess an administrative penalty not to exceed Two
Thousand Dollars ($2,000.00) for each such act . The provisions of
this subsection shall not apply to violations of subs ection G of
Section 2-309D of this title. Nothing in this section shall be
construed so as to permit the Director of the State Bureau of
Narcotics and Dangerous Drugs Control to assess administrative fines
for violations of the provisions of subsection G of Section 2-309D
Req. No. 1540 Page 28 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
of this title. Administrative penalties may be assessed per
individual transaction and incurred daily.
E. In addition to any other remedies available to the Director,
if a judge of competent ju risdiction finds probable cause that a
registrant has committed any act in violation of any law of this
state relating to any controlled substance , all controlled dangerous
substances possessed by the registrant shall be considered
contraband or hazardous material and subject to forfeiture under
Section 2-505 or 2-506 of this title as applicable, and the Director
is hereby authorized to assess a drug clea nup fine not to exceed
Fifty Thousand Dollars ($50,000.00). This drug cleanup fine shall
apply only to the registrant; provided, however, that the Director
may refuse to authorize any new registration at the same location
until such fine is pai d.
SECTION 3. AMENDATORY 63 O.S. 2021, Section 2-305, is
amended to read as follows:
Section 2-305. A. Before denying annulling, suspending or
revoking a registration , refusing a renewal of registration or
taking administrative action on a n onregistrant engaged in
manufacturing, distributing, dispensing, prescribing, administeri ng
or using for scientific purposes any controlled dange rous substance
within or into this state , the Director shall serve upon the
applicant or registrant an order to show cause why registration
should not be denied annulled, revoked, or suspended or why the
Req. No. 1540 Page 29 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
renewal should not be refused . The order to show ca use shall
contain a statement of the basis therefor and shall call upon the
applicant or registrant to appear before the appropriate person or
agency at a time and place within thirty (30) sixty (60) days after
the date of service of the order , but in the case of a denial or
renewal of registration the sho w cause order shall be served within
thirty (30) days before the expiration of the registration. These
proceedings shall be conducted in accordance with the Administrative
Procedures Act without regard to any criminal prosecution or other
proceeding. Proceedings to refuse renewal of registration shall not
abate the existing registr ation which shall remain in effect pending
the outcome of the administrati ve hearing. Nothing in this section
shall be construed so as to require an individual proceeding for t he
denial of a new registration.
B. The Director shall suspend, without an ord er to show cause,
any registration simultaneously with the institution of proceedings
under Section 2-304 of this title, if h e or she finds there is
imminent danger to the publi c health or safety which warrants this
action. The suspension shall continue i n effect until the
conclusion of the proceedings , including judicial revie w thereof,
unless sooner withdrawn by the Director or dissolved by a court of
competent jurisdiction.
C. The Director is authorized to give agents and inspectors of
the Oklahoma State Bureau of Narcotics and Dangerous Drug s Control
Req. No. 1540 Page 30 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
authority to issue cita tions for violation of any rules of the
Oklahoma State Bureau of Narcotics and Dangerous Drugs Control under
subsection D of Section 2-304 of this title. Citations shall
contain a statement of t he basis therefore and shall call upon the
registrant to appear before the appropriate person or agency at a
time and place no more than sixty (60) days after the d ate of
service of the citation.
D. The Director may authorize the Deputy Director, General
Counsel, or other designee of the Oklahoma State Bureau of Narcotics
and Dangerous Drugs Control to initiate an y individual proceeding
against a registrant provided that citations issued by agents or
inspectors are approved by the Direc tor, Deputy Director, General
Counsel, or other designee. Nothing in this section shall be
construed so as to delegate the authority of the Director to issue a
final agency order.
SECTION 4. AMENDATORY 63 O.S. 2021, Section 2 -322, is
amended to read as follows:
Section 2-322. A. No person or business shall possess, sell,
manufacture, transfer, or otherwise furnish any of the following
precursor substances wi thout first having a permit or license issued
by the Director of t he Oklahoma State Bureau of Narcotics and
Dangerous Drugs Control, except as provided in Section 2 -327 of this
title:
1. D-Lysergic acid;
Req. No. 1540 Page 31 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. Ergotamine and its salt s;
3. Ergonovine and it s salts;
4. Methylamine;
5. Ethylamine;
6. Phenyl-2-Propanone;
7. Phenylacetic acid and its salts;
8. Ephedrine, its salts, optical isomers and salts of optical
isomers;
9. Norpseudoephedrine, its salts, optical isomers, and s alts of
optical isomers;
10. Phenylpropanolamine, its salts, optical isomers and salts
of optical isomers;
11. Benzyl cyanide;
12. N-methylephedrine, its salts, optical isomers and salts of
optical isomers;
13. Pseudoephedrine, its salts, optical isome rs and salts of
optical isomers;
14. Chloroephedrine, its salts, optical isomers and salt s of
optical isomers;
15. Piperidine and its salts;
16. Pyrrolidine and its salts;
17. Propionic anhydride;
18. Isosafrole;
19. Safrole;
Req. No. 1540 Page 32 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
20. Piperonal; and
21. Red Phosphorus.
B. Upon completion of an application for a license pursuant to
Section 2-323 of this title, or a permit pursuant to Section 2 -324
of this title, the Director of the Oklahoma State Bureau of
Narcotics and Dangerous Drugs Control shall eith er grant or deny
such license or permit. A denial of an application for a permit or
license shall be handled as provided by Section 2 -325 of this title.
SECTION 5. AMENDATORY 63 O.S. 2021, Section 2 -325, is
amended to read as fol lows:
Section 2-325. A. A license or permit, obtained pursuant to
Sections 5 or 6 of this act, shall be denied annulled, suspended, or
revoked by the Director u pon finding that the licensee or pe rmit
holder has:
1. Materially falsified any application f iled pursuant to this
act or required by this act;
2. Been convicted of a misdemeanor relating to any precursor
substance defined in Section 4 of this act or any felony under the
laws of this state or the United States; or
3. Failed to maintain effective controls against the di version
of said precursors to unauthorized persons or entities.
B. Before denying annulling, suspending, or revoking a license
or permit, the Director shall cause to be ser ved upon the applicant,
licensee, or permit holder an order to show cause why a lic ense or a
Req. No. 1540 Page 33 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
permit should not be denied annulled, suspended, or revoked. The
order to show cause shall contain a s tatement of the basis the refor
and shall call upon the applicant, licensee, or permit holder to
appear before the appro priate person or agency at the time and place
within thirty (30) sixty (60) days after the date of service of the
order. The proceedings shall be c onducted in accordance with the
Administrative Procedures Act without regard to a ny criminal
prosecution or other proceeding. Nothing in this section shall be
construed so as to require an individual proceeding for the denial
of a new license or permit.
C. The Director shall suspend, without an order t o show cause,
any license or permit simultaneously with the institution of
proceedings described in subsection B of this section if he finds
there is imminent danger to the public health or safety which
warrants this action. The suspension shall continue in effect until
the conclusion of the proceedings, includin g judicial review
thereof, unless withdrawn by the Director or dissolved by a court of
competent jurisdiction.
SECTION 6. AMENDATORY 63 O.S. 2021, Section 2 -406, is
amended to read as follows:
Section 2-406. A. It shall be unlaw ful for any registrant
knowingly or intentionally:
1. To distribute, other than by dispensing or as otherwise
authorized by this act, a controlled dangerous substance classified
Req. No. 1540 Page 34 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
in Schedules I or II, in the course of his legitim ate business,
except pursuant to an order form as r equired by Section 2 -308 of
this title;
2. To use in the course of the manu facture or distribution of a
controlled dangerous substance a registration number which is
fictitious, revoked, suspended or issu ed to another person;
3. To acquire or obtain poss ession of a controlled dangerous
substance by misrepresentation, fraud, forg ery, deception or
subterfuge;
4. To furnish false or fraudulent material information in, o r
omit any material information from, any application, report, or
other document required to be kept or filed under this act, or a ny
record required to be kept by th is act; and
5. To make, distribute, or possess any punch, die, plate,
stone, or other thin g designed to print, imprint, or repro duce the
trademark, trade name, or other identifyin g mark, imprint, or device
of another or any likeness of any of the foregoin g upon any drug or
container or labeling thereof so as to render such drug a
counterfeit controlled dangerous substance .; and
6. To purchase, attempt, endeavor and conspire or endeavor or
conspire to obtain and purchase o r obtain or purchase, any license
or registration required to distribute , possess, prescribe, or
manufacture any controlled dangerous substance, on behalf of, or at
Req. No. 1540 Page 35 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
the request or demand of any person, through the use of a straw
person or party as defined in Section 2-101 of this title.
B. Any person who violates this section is guilty of a felony
punishable by imprisonment for not more than twenty (20) years or a
fine of not more than Two Hu ndred Fifty Thousand Dollars
($250,000.00), or both.
C. Any person convicted of a second or subsequent violation of
this section is punishable by a term of imprisonment twice that
otherwise authorized and by twice the fine othe rwise authorized.
Convictions for second or subsequent violations of this section
shall not be subject to statutory provisions for suspended
sentences, deferred sentences, or probation.
D. Any person convicted of any offense described in this
section shall, in addition to any fine imposed, pay a special
assessment trauma-care fee of One Hundred Dol lars ($100.00) to be
deposited into the Trauma Care Assistance Revolving Fund created in
Section 1-2522 of this title.
SECTION 7. It being immediately necessary for the pr eservation
of the public peace, health or safety, an emergency is hereby
declared to exist, by re ason whereof this act shall take ef fect and
be in full force from and after its passage an d approval.
59-1-1540 JES 1/17/2023 1:13:42 PM